Phathom Pharmaceuticals, Inc.

NasdaqGS PHAT

Phathom Pharmaceuticals, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -1,292.14%

Phathom Pharmaceuticals, Inc. Net Income Margin is -1,292.14% for the Trailing 12 Months (TTM) ending September 30, 2024. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqGS: PHAT

Phathom Pharmaceuticals, Inc.

CEO	Ms. Terrie J. Curran
IPO Date	Oct. 25, 2019
Location	United States
Headquarters	100 Campus Drive
Employees	452
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Vaccines

Description

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Key trends

Past 5 years